AstraZeneca PLC
ZEG
Company Profile
Business description
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Contact
1 Francis Crick Avenue
Cambridge Biomedical Campus
CambridgeCB2 0AA
GBRT: +44 2037495000
E: ir@astrazeneca.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
94,300
Stocks News & Analysis
stocks
Picking dividend shares in 2026? Here’s where to look
A new report from Morningstar shows opportunities for income investors.
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
With outstanding long-term estimates, here’s what we think of Nvidia stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,738.30 | 118.30 | -1.34% |
| CAC 40 | 7,974.76 | 144.26 | -1.78% |
| DAX 40 | 23,182.80 | 407.72 | -1.73% |
| Dow JONES (US) | 46,590.24 | 557.24 | -1.18% |
| FTSE 100 | 9,530.61 | 144.82 | -1.50% |
| HKSE | 25,930.03 | 454.25 | -1.72% |
| NASDAQ | 22,708.07 | 192.52 | -0.84% |
| Nikkei 225 | 48,702.98 | 1,620.93 | -3.22% |
| NZX 50 Index | 13,342.82 | 156.22 | -1.16% |
| S&P 500 | 6,672.41 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,469.10 | 109.70 | -1.28% |
| SSE Composite Index | 3,939.81 | 32.22 | -0.81% |